[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617913":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":43,"collaborators":20,"id":47,"slug":20,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":20,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental arm","EXPERIMENTAL","Pts will receive adaptive boost for clinically significant disease",[13],"Radiation: adaptive RT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","adaptive RT","Prostate cancer pts post-prostatectomy：95%PTVboost 7Gy\u002F3.5Gy\u002F2f，95%PTV 66Gy\u002F2.0Gy\u002F33f，w\u002Fo 95%PTVp 50Gy\u002F2.0Gy\u002F25f Bladder cancer pts with bladder-conserving txt：95%PGTV 18Gy\u002F6.0Gy\u002F3f，95%PTV 50Gy\u002F2.0Gy\u002F25f，w\u002Fo 95%PTVp 50Gy\u002F2.0Gy\u002F25f",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Ning-Ning Lu, M.D.","CONTACT","861018611804268","ningninglu09@163.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Cancer Hospital, National Cancer Center, CAMS & PUMC","RECRUITING","Beijing","Beijing Municipality","100021","China",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},[42],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","NINGNING LU","Principal Investigator","100617913",false,"NCT07324798","Adaptive Radiotherapy for Genitourinary Cancers","Prospective Study of siMultaneous Adaptive RadioTherapy for Local Boost for Prostate and Bladder Cancers (SMART-B01)","SMART-B01","Inclusion Criteria:\n\n* Patients with newly diagnosed or metastatic\u002Frecurrent pathologically confirmed urological tumors, clinically assessed as suitable for adaptive radiotherapy;\n* Age ≥ 18 years;\n* ECOG performance status score 0-2;\n* No prior radiotherapy history within the current radiation field;\n* No contraindications for MRI scanning;\n* No contraindications for radiotherapy.\n\nExclusion Criteria:\n\n* Patients with contraindications to radiotherapy;\n* Patients unable to tolerate MRI or with contraindications to MRI scanning.","MALE","18 Years",{"count":57,"type":58},60,"ESTIMATED","INTERVENTIONAL",[61],"NA","The goal of this clinical trial is to learn if adaptive radiation boost works to treat genitourinary cancers, esp. in the context of prostate cancer patients with post-prostatectomy local relapse and bladder cancer patients with bladder-conserving treatment. It will also learn about the safety and efficacy of adaptive boost. The main questions it aims to answer are:\n\nDoes adaptive boost lower the toxicities? Does adaptive boost maintain or improve the clinical efficacy?\n\nParticipants will:\n\nUndergo adaptive boost on 1.5-Tesla MR-Linac Visit the clinic once every 2 weeks during RT, and every 3 months post-ART Keep a regular QOL questinnaire completion",[64,65],"Prostate Cancer (Post Prostatectomy)","Bladder Cancer",[67,68,69,70,71],"prostate cancer","bladder cancer","adaptive radiotherapy","post-prostatectomy","bladder-conserving treatment","2025-12-29",{"date":74,"type":75},"2026-01-07","ACTUAL",{"date":77,"type":75},"2024-12-01",{"date":79,"type":58},"2028-12-31",{"name":5,"class":6},1]